Drug delivery

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Begins IND Enabling Studies of Envelta(TM)

Tuesday, February 23, 2021 - 1:11pm

Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.

Key Points: 
  • Anthony P. Mack, Chairman and CEO of Virpax stated, "The commencement of these critical pre-clinical studies takes us one step closer to the clinic.
  • Dr. Jeffrey Gudin, principal investigator and co-founder of Virpax, has been working in partnership with the NCATS since we announced the CRADA in August 2020.
  • Envelta(TM) is an intranasal enkephalin drug product candidate formulation based on nanotechnology which enables the delivery of the drug product to the brain.
  • Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery.

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQ™-Based Disintegrating THC Oral Film

Wednesday, February 17, 2021 - 1:00pm

This film formulation patent covers novel disintegrating oral film formulations designed for the transmucosal absorption of drug, especially tetrahydrocannabinol (THC), and is intended to protect IntelGenxs DisinteQTM products.

Key Points: 
  • This film formulation patent covers novel disintegrating oral film formulations designed for the transmucosal absorption of drug, especially tetrahydrocannabinol (THC), and is intended to protect IntelGenxs DisinteQTM products.
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.
  • This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties.

SmallCapsDaily: Lobe Sciences is a Major Opportunity In the Psychedelics Medicine Industry

Friday, February 12, 2021 - 6:52pm

Highlighted in the SmallCapsDaily reporting, is the unique company overview and the core offerings of Lobe Sciences.

Key Points: 
  • Highlighted in the SmallCapsDaily reporting, is the unique company overview and the core offerings of Lobe Sciences.
  • Additionally, Lobe is working towards creating devices and improved delivery mechanisms for the efficient application of medications.
  • Lobe has intellectual property and has strategically acquired brands related to the psychedelic drug therapy industry, which can lead to lucrative licensing and partnerships.
  • The SmallCapsDaily coverage of Lobe Sciences proves to be a comprehensive exploration of the company's unique IP assets, its positioning within the industry and the opportunity Lobe represents to stakeholders monitoring changes within the psychedelic medicine, drug therapy and drug delivery industries.

Global Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems Market Report 2020-2025 with Profiles of Bristol-Myers Squibb Co., GSK, Hofmann-La Roche, Merck & Co., and Novartis

Monday, January 25, 2021 - 2:30pm

DUBLIN, Jan. 25, 2021 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 25, 2021 /PRNewswire/ -- The "Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
  • The report includes an analysis of leading and emerging drug products for each nanoparticle type.
  • The most rapid advances have been made in the application of nanoparticles in drug research and development, drug product formulation, and development of novel drug delivery systems using nanoparticle carriers.
  • Drug formulation and delivery are attracting new players in Europe, and this in turn will contribute to the market's growth.

Global Injectable Drug Delivery Devices Pipeline Assessment Report 2020 - ResearchAndMarkets.com

Thursday, January 14, 2021 - 12:14pm

The "Injectable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Injectable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering.
  • "Injectable Drug Delivery Devices - Medical Devices Pipeline Assessment, 2020".
  • Injectable Drug Delivery Devices are defined as administration of a drug into patient's blood through a delivery device.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    In-depth analysis of the product's current stage of development, territory and estimated launch date

Global Cardiovascular Drug Delivery Technologies, Companies & Markets to 2028: Focus on Cell Therapy, Gene Therapy, Drug-Eluting Stents

Monday, January 11, 2021 - 5:45pm

The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.

Key Points: 
  • The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.
  • The role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
  • Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases.
  • Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides.

Updated Cardiovascular Drug Delivery Report 2020 - Global Technologies, Markets & Companies Forecast to 2028 - ResearchAndMarkets.com

Friday, January 8, 2021 - 11:41am

The "Cardiovascular Drug Delivery - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiovascular Drug Delivery - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.
  • The role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
  • Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases.

Oramed to Present at H.C. Wainwright BioConnect 2021 Conference

Thursday, January 7, 2021 - 1:40pm

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021.The presentation will be available on demand to conference participants as of January 11.

Key Points: 
  • NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright BioConnect 2021 Conference, held virtually from January 11-14, 2021.The presentation will be available on demand to conference participants as of January 11.
  • Oramed Pharmaceuticalsis a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices inNew YorkandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology.
  • For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Worldwide Industry for Advanced Drug Delivery Systems to 2025 - Featuring Alcon, Baxter International and Novartis Among Others

Thursday, January 7, 2021 - 1:15pm

This report represents a current and important business tool to evaluate technologies, trends, products, and market participants in the advanced drug delivery sector.

Key Points: 
  • This report represents a current and important business tool to evaluate technologies, trends, products, and market participants in the advanced drug delivery sector.
  • The report identifies the main elements of advanced drug delivery products and trends in different types of industries.
  • Advanced drug delivery systems (ADDS) refer to the technologies used for controlling the rate of drug release.
  • Advanced drug delivery is an attractive industry with multifaceted growth opportunities in research and development, technologies, applications, and formulations.

2020 Insights on the Global Markets and Technologies for Advanced Drug Delivery Systems - ResearchAndMarkets.com

Tuesday, January 5, 2021 - 4:42pm

The "Global Markets and Technologies for Advanced Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Markets and Technologies for Advanced Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
  • This report represents a current and important business tool to evaluate technologies, trends, products, and market participants in the advanced drug delivery sector.
  • The report identifies the main elements of advanced drug delivery products and trends in different types of industries.
  • Advanced drug delivery systems (ADDS) refer to the technologies used for controlling the rate of drug release.